Literature DB >> 24282467

Variations in prostate biopsy practice: A quantitative questionnaire-based study.

Matthew O Lipinski1, D Robert Siemens, Patti A Groome.   

Abstract

BACKGROUND: The ambivalent results of recent large randomized prostate cancer studies have added a significant layer of uncertainty for clinicians and patients contemplating investigation of early disease. This uncertainty and lack of prescriptive recommendations from professional organizations has led to significant variation in practice in North America. The purpose of this study was to determine the extent of variation in biopsy recommendations by urologists and to discern factors predictive for these recommendations.
METHODS: An anonymous, cross-sectional, self-report questionnaire was sent to all active members of the Canadian Urological Association practicing in Ontario. The survey consisted of demographic data and 10 closed-ended questions designed to capture biopsy preferences in ambiguous clinical situations. Respondent preferences for recommending a prostate biopsy were compared to a guideline-informed study standard. Descriptive and correlative statistics were used to analyze the responses.
RESULTS: The response rate to the survey was 74%. The responses showed considerable variability in recommendations for or against biopsy. While most of the urologists concurred with the research team's study standard recommendations, only 4 scenarios had over 80% concurrence and 1 scenario, which centered on the utility of free PSA, had only had 42% concurrence. None of the respondent's descriptors were associated with trends to recommend biopsy other than the number of biopsies performed per year (p = 0.04).
INTERPRETATION: This self-report survey investigating prostate biopsy thresholds identifies considerable variation in practicing urologists in Ontario. The drivers of biopsy recommendations in these relatively ambiguous clinical situations appeared to be age, suspicious rectal examinations, and total PSA.

Entities:  

Year:  2013        PMID: 24282467      PMCID: PMC3840526          DOI: 10.5489/cuaj.372

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  19 in total

1.  Prostate cancer screening: Canadian guidelines 2011.

Authors:  Jonathan I Izawa; Laurence Klotz; D Robert Siemens; Wassim Kassouf; Alan So; John Jordan; Michael Chetner; Alla E Iansavichene
Journal:  Can Urol Assoc J       Date:  2011-08       Impact factor: 1.862

2.  Determinants of prostate-specific antigen test use in prostate cancer screening by primary care physicians.

Authors:  O J Austin; S Valente; L A Hasse; J R Kues
Journal:  Arch Fam Med       Date:  1997 Sep-Oct

3.  Prostate-specific antigen test result interpretation when combined with risk factors for recommendation of biopsy: a survey of urologist's practice patterns.

Authors:  Nathan Lawrentschuk; Nikhil Daljeet; Clement Ma; Karen Hersey; Alexandre Zlotta; Neil Fleshner
Journal:  Int Urol Nephrol       Date:  2010-06-12       Impact factor: 2.370

4.  Trends and risk factors for prostate biopsy complications in the pre-PSA and PSA eras, 1980 to 1997.

Authors:  Rosebud O Roberts; Erik J Bergstralh; Jennifer A Besse; Michael M Lieber; Steven J Jacobsen
Journal:  Urology       Date:  2002-01       Impact factor: 2.649

5.  Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program.

Authors:  René Raaijmakers; Wim J Kirkels; Monique J Roobol; Mark F Wildhagen; Fritz H Schrder
Journal:  Urology       Date:  2002-11       Impact factor: 2.649

6.  Multiple transrectal ultrasound guided prostatic biopsies: morbidity and tolerance.

Authors:  C Deliveliotis; V John; G Louras; S Andreas; E Alargof; F Sofras; N Goulandris
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

7.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

8.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

9.  Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination.

Authors:  Patrik Finne; Anssi Auvinen; Jussi Aro; Harri Juusela; Liisa Määttänen; Sakari Rannikko; Matti Hakama; Teuvo L J Tammela; Ulf-Håkan Stenman
Journal:  Eur Urol       Date:  2002-06       Impact factor: 20.096

10.  Major complications and associated risk factors of transrectal ultrasound guided prostate needle biopsy: a retrospective study of 1875 cases in taiwan.

Authors:  I-Ni Chiang; Shang-Jen Chang; Yeong-Shiau Pu; Kuo-How Huang; Hong-Jen Yu; Chao-Yuan Huang
Journal:  J Formos Med Assoc       Date:  2007-11       Impact factor: 3.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.